Journal: Frontiers in Medicine

Article Title: Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment

doi: 10.3389/fmed.2023.1195747

Figure Lengend Snippet: Anti-MAA, anti-AGE, anti-CarP, and anti-AL antibodies are increased in patients with AILD, and especially in patients with AIH. IgG antibody levels are presented as arbitrary units per milliliter (aU/mL) and cut-off for each PTM is indicated by the dashed line. * p < 0.05, ** p < 0.01. Autoimmune Liver Disease: AIH, PBC and PSC; non-Autoimmune Liver Disease: NAFLD, HCV, HBV, ALD, Combination, NASH. AGE, advanced glycation end-product; AIH, autoimmune hepatitis; AL, acetylated protein; CarP, carbamylated protein; Cit, citrullinated protein; MAA, malondialdehyde–acetaldehyde adduct; ns, not significant; NT, nitrated protein.

Article Snippet: We did not observe a significant difference in the presence of anti-PTM antibodies in patients positive or negative for ANA or SMA, with the exception of anti-MAA positivity and ANA positivity in patients with AIH (Chi-2 (1) > = 4.687, p = 0.030).

Techniques:

Journal: Frontiers in Medicine

Article Title: Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment

doi: 10.3389/fmed.2023.1195747

Figure Lengend Snippet: Patients with AILD, and especially AIH, are more likely to be positive for more than one anti-PTM antibody. Data is presented as percentage positive (%) patients for a number of anti-PTM antibodies in (from left to right) healthy controls, non-autoimmune liver disease autoimmune liver disease and autoimmune hepatitis.

Article Snippet: We did not observe a significant difference in the presence of anti-PTM antibodies in patients positive or negative for ANA or SMA, with the exception of anti-MAA positivity and ANA positivity in patients with AIH (Chi-2 (1) > = 4.687, p = 0.030).

Techniques:

Journal: Frontiers in Medicine

Article Title: Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment

doi: 10.3389/fmed.2023.1195747

Figure Lengend Snippet: The association between the presence of anti-PTM antibodies in HC, non-AILD, AIH and cholestatic liver disease.

Article Snippet: We did not observe a significant difference in the presence of anti-PTM antibodies in patients positive or negative for ANA or SMA, with the exception of anti-MAA positivity and ANA positivity in patients with AIH (Chi-2 (1) > = 4.687, p = 0.030).

Techniques:

Journal: Frontiers in Medicine

Article Title: Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment

doi: 10.3389/fmed.2023.1195747

Figure Lengend Snippet: Percentage of positivity for anti-PTM antibodies in ANA positive, ANA negative, SMA positive, SMA negative and double negative (ANA and SMA) patients with AIH.

Article Snippet: We did not observe a significant difference in the presence of anti-PTM antibodies in patients positive or negative for ANA or SMA, with the exception of anti-MAA positivity and ANA positivity in patients with AIH (Chi-2 (1) > = 4.687, p = 0.030).

Techniques:

Journal: Frontiers in Medicine

Article Title: Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment

doi: 10.3389/fmed.2023.1195747

Figure Lengend Snippet: Characteristics of untreated AIH patients in the AILD cohort ( n = 58).

Article Snippet: We did not observe a significant difference in the presence of anti-PTM antibodies in patients positive or negative for ANA or SMA, with the exception of anti-MAA positivity and ANA positivity in patients with AIH (Chi-2 (1) > = 4.687, p = 0.030).

Techniques: Biomarker Discovery

Journal: Frontiers in Medicine

Article Title: Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment

doi: 10.3389/fmed.2023.1195747

Figure Lengend Snippet: Levels of (A) ALAT, ASAT, IgG and (B) anti-PTM antibodies over time in patients with AIH ( n = 25). ALAT, ASAT and IgG levels were determined as standard procedure after inclusion. V1: before commencing treatment, V2: during treatment. Median time interval: 65 months (6–138). Reactivity toward anti-PTM antibodies was determined using ELISA and is depicted as arbitrary units per milliliter (aU/mL). * p = 0.0244 and **** p ≤ 0.0001. AGE, advanced glycation end-product; AL, acetylated protein; ALAT, Alanine aminotransferase; ASAT, Aspartate aminotransferase; CarP, carbamylated protein; IgG, immunoglobulin gamma; MAA, malondialdehyde–acetaldehyde adduct; V1, first visit; V2, second visit.

Article Snippet: We did not observe a significant difference in the presence of anti-PTM antibodies in patients positive or negative for ANA or SMA, with the exception of anti-MAA positivity and ANA positivity in patients with AIH (Chi-2 (1) > = 4.687, p = 0.030).

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Frontiers in Immunology

Article Title: COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review

doi: 10.3389/fimmu.2022.872683

Figure Lengend Snippet: A brief summary of studies addressing immune and autoimmune side effects of COVID-19 vaccines.

Article Snippet: , AstraZeneca (ChAdOx1) , Rela et al. ( ) , 2 cases of AIH following 1 st vaccination , There were no clear clinical or biochemical features apart from a chronological association to differentiate patients’ vaccine-related AIH from idiopathic AIH..

Techniques: Vaccines, Biomarker Discovery, Infection, Diagnostic Assay, Injection, Imaging, Plasmid Preparation, Clinical Proteomics, Variant Assay, Coagulation, Activity Assay, Sequencing, Produced, Activation Assay

Journal: Cureus

Article Title: COVID-19 Vaccination-Induced Cholangiopathy and Autoimmune Hepatitis: A Series of Two Cases

doi: 10.7759/cureus.30304

Figure Lengend Snippet: Updated RUCAM for the hepatocellular injury of DILI and HILI RUCAM: Roussel Uclaf Causality Assessment Method scale; DILI: Drug-induced liver injury; HILI: Herb-induced liver injury (HILI) [ 17 ] * Group I (7 causes) HAV: Anti-HAV-IgM, Hepatobiliary sonography/color Doppler, HCV: Anti-HCV, HCV-RNA, HEV: Anti-HEV-IgM, anti-HEV-IgG, HEV-RNA, Hepatobiliary sonography/color Doppler sonography of liver vessels/ endo-sonography/CT/MRC, Alcoholism (AST/ALT ≥ 2), Acute recent hypotension history (particularly if underlying heart disease), *Group II (5 causes) Complications of underlying disease(s) such as sepsis, metastatic malignancy, autoimmune hepatitis, chronic hepatitis B or C, primary biliary cholangitis or sclerosing cholangitis, genetic liver diseases, Infection suggested by PCR and titer change for; CMV (anti-CMV-IgM, anti-CMV-IgG), EBV (anti-EBV-IgM, anti-EBV-IgG), HSV (anti-HSV-IgM, anti-HSV-IgG), VZV (anti-VZV-IgM, anti-VZV-IgG). **Patient's ALT 689 U/L, Upper limit of normal ALT 40 U/L, Patient's ALP 213 U/L, Upper limit of normal ALP 120 U/L, R-value 9.7, RUCAM score > 5. The hepatocellular pattern of liver injury. Recommend acute viral hepatitis serologies, HCV RNA and autoimmune hepatitis serologies, and imaging studies such as abdominal ultrasound) [ 18 ].

Article Snippet: A recent mention of AIH post-BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccination has been published by Fimiano et al. [ ] who reported a patient with AIH post-COVID-19 vaccination and suggested an increase in prevalence, and hence a need for increased awareness of possible COVID-19 vaccine-induced AIH [ ].

Techniques: Infection, Imaging